Article
Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia
2020-11-04
Abstract excerpt
Background: Recent randomized trials have demonstrated improvements in overall survival (OS) for the BCL-2 inhibitor venetoclax (VEN) in combination with azacitidine and low dose cytarabine in older unfit patients with AML. Pre-clinical studies identified BAX deficiency as a potential mechanism of VEN resistance in AML, but this has not been observed in patients to date (Chen, Cancer Disc 2019). Methods: Patient s...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 9301f4eb-5a5e-51b7-a792-b248b319de09
- DOI
- 10.1182/blood-2020-136872
